Speakers Urge More Dry Eye Disease Research As Vision Community Recognizes Dry Eye Awareness Month 2019 with Capitol Hill Briefing and Screening
Left to right: The Briefing faculty consisted of Bridgitte Shen Lee, OD (Vision Optique), AEVR Executive Director James Jorkasky, Tear Film & Ocular Surface Society Executive Director Amy Gallant Sullivan, Deborah S. Jacobs, MD (Mass Eye & Ear/Harvard Medical School), David A. Sullivan, MS, PhD (Schepens Eye Research Institute/Harvard Medical School and TFOS Founder) and Victor Perez Quinones, MD (Duke University)
On July 10, AEVR and the Tear Film & Ocular Surface Society (TFOS) joined with the vision community and coalition partners (see bottom box) in recognizing July 2019 as Dry Eye Awareness Month. This was the third year of this event which included a Congressional Briefing and Test Your Tears Dry Eye Screening, along with Congressional delegation visits managed by the National Alliance for Eye and Vision Research (NAEVR). The Briefing focused on the TFOS Dry Eye Workshop II Report (TFOS DEWS II), published in The Ocular Surface journal in July 2017, and how it has impacted clinical practice and research. TFOS DEWS II was the first re-examination of the topic since the initial TFOS DEWS report issued in 2007, updating the definition, classification, and diagnosis of dry eye; critically evaluating the epidemiology, pathophysiology, mechanism, and impact of the disease; addressing its management and therapy; and developing recommendations for the design of clinical trials to assess pharmaceutical interventions.
About Dry Eye and Areas of TFOS DEWSII Focus
Dry Eye Disease (DED) is the most frequent cause of patient visits to eye care providers and has a significant impact on healthcare policy as it affects more than 30 million Americans and costs the United States healthcare system $3.8 billion annually, with a $55.4 billion annual cost to society from diminished productivity. Dry eye occurs when the eye does not produce tears properly or when the tears are not of the correct consistency and evaporate too quickly. For some people, dry eye feels like a speck of sand in the eye, or a stinging or burning that does not go away. For others, it can become a painful chronic and progressive condition that leads to blurred vision or even vision loss if it goes untreated. Moderate-to-severe dry eye is associated with significant pain, role limitations, low vitality, poor general health, and often depression. There is no cure for DEDat best, eye care professionals manage the disease.
TFOS Executive Director Amy Gallant Sullivan moderated a panel of four speakers, which included eyecare professionals who were among the 150 experts from 23 countries who participated in the TFOS DEWS II initiative.
Iatrogenic Dry Eye:
Clinician-scientist Victor Perez Quinones, MD (Duke University), who announced to the audience that he owes his career to National Institutes of Health (NIH) funding, addressed iatrogenic dry eye, disease which is induced unintentionally by the medical treatment by a physician. He noted that contact lens wear, topical and systemic drugs, and certain ophthalmic procedures (refractive surgery, keratoplasty, cataract removal, and lid surgery) can all result in dry eye. While emphasizing the importance of patients speaking with their eyecare professionals about the potential impact of any of these interventions, he also stated that eyecare professionals need to increasingly look at ways to reduce potential iatrogenic events.
Clinician-scientist Deborah S. Jacobs, MD (Mass Eye and Ear/Harvard Medical School) spoke about the basis of ocular pain, stating that nerves besides the ones that transmit light signalsare an important part of the eye and that they participate in the homeostasis or stability of the ocular surface. Noting that diseases of the back-of-the-eye (glaucoma, macular degeneration, and diabetic eye disease) generally do not result in pain, diseases of the front-of-the eye often result in pain or discomfort. Ocular pain can result from dry eye, as well as corneal injury, headache, and Traumatic Brain Injury. Nerves are the basis for dry eye symptoms, often manifested as foreign body sensation, grittiness, ice pick (sharp) pain, and photophobia or light sensitivity. She reported that, although the NIH/National Eye Institute (NEI) are supporting several grants related to the causes of and treatments for pain, further research is needed.
Dry Eye in Children:
Clinician Bridgitte Shen Lee, OD (Vision Optique) spoke about the growing public ocular health problem of dry eye in children and teens, since earlier or younger onset can lead to more severe presentations of the disease. It can result from a variety of sources, including meibomian gland dysfunction (MGD) or changes to or degradation of the meibomian glands, which produce the lipid necessary for healthy tear film due to poor lids and lashes hygiene, cosmetic ingredients and application, and digital screen usage and habits that can result in insufficient blinking and lead to unstable tear film. Citing limited research data, she urged more research into dry eye in the pediatric population, as there has been just one US-based study to-date on the prevalence of meibomian gland dysfunction in children and teens.
Innovation in Research
David A. Sullivan, MS, PhD (Schepens Eye Research Institute/Harvard Medical School and TFOS Founder) spoke about the impact of innovation coupled with NEI funding. He stated that NEI support permitted him and colleagues to begin testing their innovative hypothesis that topical lubricin would serve as a safe and effective therapy for the treatment of dry eye disease. Lubricin is the body's unique anti-friction, anti-adhesive, anti-fibrotic and anti-inflammatory glycoprotein. Their findings supported their hypothesis and prompted a multi-year effort to make recombinant human lubricin and to translate their basic research discovery into a clinical treatment for dry eye. Their efforts have led to a recent and successful clinical trial in Europe, as well as to discoveries by multiple researchers that this recombinant human lubricin may be a possible therapy for many other conditions, including dry mouth, osteoarthritis, gout and post-surgical adhesions. In effect, innovation and NEI funding can have a very far-reaching impact.
TearLab Conducts Test Your Tears Dry Eye Screening
Prior to and after the Briefing, Benjamin D. Sullivan, PhD, Founder and Chief Scientific Officer of TearLab, conducted the Test Your Tears screening using the TearLab Osmolarity System, which measures osmolarity of human tears to aid in the diagnosis of dry eye disease, in conjunction with other methods of clinical evaluation. Osmolarity is an important biomarker of ocular surface health.
Among the many attendees tested was Phyllis Greenberger of Healthy Women.
Briefing Faculty Educates Congressional Delegations
Under the auspices of NAEVR, the speakers visited their Congressional delegation offices to describe their dry eye clinical practice and research, as well as request robust NIH/NEI funding in Fiscal Year (FY) 2020 appropriations.
Dr. Jacobs with Cong. Joe Kennedy (D-MA). Dr. Jacobs is holding a photo of herself with the late Sen. Ted Kennedy, Cong. Kennedy's uncle, during a trip to Washington, DC in 1977.
Rachel Soclof, office of Senator Richard Burr (R-NC) with Dr. Perez
From left: Alex Davidson, office of Sen. Elizabeth Warren (D-MA), Ms. Sullivan, Dr. Jacobs, and Dr. Sullivan
Jeffrey Last, office of Sen. John Cornyn (R-TX), with Dr. Shen Lee
Joining AEVR and TFOS, the following vision community and its coalition partners signed onto a June 10 press release to support the July 2019 Dry Eye Awareness Month educational activities, including:
|Alliance for Eye and Vision Research||Healthy Women|
|American Academy of Ophthalmology||Prevent Blindness|
|American Academy of Optometry||Research to Prevent Blindness|
|American Optometric Association||Sjögrens Syndrome Foundation|
|Association for Research in Vision
|Tear Film & Ocular Surface Society
Womens Eye Health
AEVR thanks Takeda for its support for event management.
TFOS thanks the following industry partners who supported TFOS DEWS II with unrestricted donations, including: Alcon, Novartis Pharmaceuticals Corporation, Shire, Allergan, Bausch+Lomb, Akorn, CooperVision, Dompé, Horus Pharma, Lµbris Biopharma, Oculeve, TearLab, Laboratoires Théa, SIFI, Johnson & Johnson Vision, Quint Health, Scope Ophthalmics, Sun Pharma, Carl Zeiss Meditec, Inc. ZEISS Group, and Senju.